title: An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes.
abstract: The effect of herpesvirus co-infections (HHV-6, HHV-7) on cytomegalovirus (CMV) disease and its response to therapy is unknown. We prospectively analyzed herpesvirus co-infections in transplant recipients with CMV disease. All patients received 3 weeks of antiviral therapy. Samples were collected at baseline (day 0) and then day 3, 7, 14 and 21 poststart of therapy. Viral load testing for CMV, HHV-6 and HHV-7 was done using quantitative PCR assays in 302 patients of whom 256 had documented symptomatic CMV viremia. In this subset, day 0 HHV-6 co-infection was present in 23/253 (9.1%) and HHV-7 in 17/253 (6.7%). Including those positive at any time point raised the prevalence to 79/256 (30.9%) for HHV-6 and 75/256 (29.3%) for HHV-7. Viral co-infection did not influence the response of CMV disease to antiviral therapy. Baseline CMV viral loads, time to eradication and risk of recurrence were similar in patients with and without HHV-6 or HHV-7 co-infection. Ganciclovir and valganciclovir had no clear effect on HHV-6 and HHV-7 viremia. In conclusion, herpesvirus co-infections are common in patients with CMV disease but with standard antiviral therapy, no clear clinical effects are discernable. Routine monitoring for viral co-infection in patients with CMV disease is not indicated.
authors.affiliation: Department of Medicine, University of Alberta, Edmonton, AB, Canada. ahumar@ualberta.ca
authors.forename: A
authors.initials: A
authors.lastname: Humar
authors.forename: A
authors.initials: A
authors.lastname: Asberg
authors.forename: D
authors.initials: D
authors.lastname: Kumar
authors.forename: A
authors.initials: A
authors.lastname: Hartmann
authors.forename: G
authors.initials: G
authors.lastname: Moussa
authors.forename: A
authors.initials: A
authors.lastname: Jardine
authors.forename: H
authors.initials: H
authors.lastname: Rollag
authors.forename: H
authors.initials: H
authors.lastname: Mouas
authors.forename: C G
authors.initials: CG
authors.lastname: Gahlemann
authors.forename: M D
authors.initials: MD
authors.lastname: Pescovitz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D015331:Cohort Studies; D003587:Cytomegalovirus / Q000235:genetics / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000150:complications* / Q000821:virology; D004279:DNA, Viral / Q000235:genetics; D015774:Ganciclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D015654:Herpesvirus 6, Human / Q000235:genetics / Q000302:isolation & purification*; D016199:Herpesvirus 7, Human / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D015994:Incidence; D007390:International Agencies; D008875:Middle Aged; D016377:Organ Transplantation; D016133:Polymerase Chain Reaction; D011183:Postoperative Complications / Q000453:epidemiology / Q000821:virology*; D011446:Prospective Studies; D019349:Roseolovirus Infections / Q000150:complications* / Q000821:virology; D016896:Treatment Outcome; D000077562:Valganciclovir; D019562:Viral Load; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D000077562:Valganciclovir; D015774:Ganciclovir